Johnson & Johnson (JNJ) : Albion Financial Group Ut scooped up 90 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 15,964 shares of Johnson & Johnson which is valued at $1,809,040.Johnson & Johnson makes up approximately 0.30% of Albion Financial Group Ut’s portfolio.
Johnson & Johnson closed down -0.14 points or -0.12% at $112.77 with 57,59,301 shares getting traded on Wednesday. Post opening the session at $112.96, the shares hit an intraday low of $112.46 and an intraday high of $113.2 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Paradigm Financial Advisors added JNJ to its portfolio by purchasing 2,010 company shares during the most recent quarter which is valued at $227,773. Johnson & Johnson makes up approx 0.14% of Paradigm Financial Advisors’s portfolio.Capital One National Association reduced its stake in JNJ by selling 11,658 shares or 8.05% in the most recent quarter. The Hedge Fund company now holds 133,117 shares of JNJ which is valued at $15,084,818. Johnson & Johnson makes up approx 1.35% of Capital One National Association’s portfolio.Alpha Windward reduced its stake in JNJ by selling 81 shares or 2.86% in the most recent quarter. The Hedge Fund company now holds 2,755 shares of JNJ which is valued at $303,546. Johnson & Johnson makes up approx 0.22% of Alpha Windward’s portfolio.Taylor Wealth Management Partners boosted its stake in JNJ in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 1,485 shares of Johnson & Johnson which is valued at $163,617. Johnson & Johnson makes up approx 0.08% of Taylor Wealth Management Partners’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.